Clinical Oncology - Issue 3/2025
Original Articles
192
Real-world PD-L1 testing, fi rst-line therapy for advanced NSCLC, and fi rst-line pembrolizumab monotherapy utilization and outcomes for metastatic NSCLC in the Czech Republic
M. L. Santorelli, M. Chrápavá, K. Hrabcová, G. Bencina, J. Blažek, M. Bratová, O. Fibigr, #, O. Fischer, L. Koubková, J. Krejčí, A. Ryška, P. Zemanová, T. Burke
201
Total mesometrial resection for the treatment of cervical cancer – an exploratory study of feasibility, safety and oncological outcomes in developing countries
P. Sorokin, S. Kulikova, A. Stepanyan, H. Davtyan, M. Kuryllo, R. Oliveira, B. Rezende
Editorial
Reviews
177
Cancer in the elderly in Slovakia
M. Ondrušová, S. Vándor Svidová, A. Blažová, D. Ondruš
185
Current complex treatment for cervical cancer
R. Soumarová, J. Havlík
Case Reports
213
Long-term treatment effi cacy in a rapid growth malignant undiff erentiated lung tumor
Y. Maezawa, Y. Sasatani, G. Ohara, S. Okauchi, H. Kawai, H. Satoh
Short Communication
218
224
Extravasation (paravasation) of anticancer drugs – updated recommendations (2025) for standard care in the Czech Republic based on multidisciplinary cooperation
S. Vokurka, V. Maňásek, D. Navrátilová Hrabánková, P. Rozsívalová, J. Kletečka, S. Šípová, V. Pavlicová, P. Žák, Š. Kozáková, A. Vlasáková, D. Brojáčová, L. Turková, B. Víšek
Clinical Oncology
2025 Issue 3
Most read in this issue
- Extravasation (paravasation) of anticancer drugs – updated recommendations (2025) for standard care in the Czech Republic based on multidisciplinary cooperation
- Present management of gastrointestinal stromal tumors
- Real-world PD-L1 testing, fi rst-line therapy for advanced NSCLC, and fi rst-line pembrolizumab monotherapy utilization and outcomes for metastatic NSCLC in the Czech Republic
- Practical recommendations for the use of PARP inhibitors in the treatment of ovarian cancer